Literature DB >> 32895239

Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo et al.

Kimme L Hyrich1, Milena Gianfrancesco2, Pedro M Machado3,4, Jinoos Yazdany5, Philip C Robinson6,7.   

Abstract

Entities:  

Keywords:  autoimmunity; glucocorticoids; inflammation

Mesh：

Substances：

Year:  2020        PMID： 32895239     DOI： 10.1136/annrheumdis-2020-218910

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   27.973


× No keyword cloud information.
  3 in total

1.  COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study.

Authors:  Kristin M D'Silva; April Jorge; Andrew Cohen; Natalie McCormick; Yuqing Zhang; Zachary S Wallace; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2021-05-01       Impact factor: 15.483

2.  [German registry www.Covid19-Rheuma.de : Status report after 1 year of the pandemic].

Authors:  Rebecca Hasseli; Alexander Pfeil; Bimba Franziska Hoyer; Hanns-Martin Lorenz; Anne C Regierer; Jutta G Richter; Tim Schmeiser; Anja Strangfeld; Reinhard E Voll; Andreas Krause; Hendrik Schulze-Koops; Ulf Müller-Ladner; Christof Specker
Journal:  Z Rheumatol       Date:  2021-07-01       Impact factor: 1.372

Review 3.  COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges.

Authors:  Saikat Dewanjee; Ramesh Kandimalla; Rajkumar Singh Kalra; Chandrasekhar Valupadas; Jayalakshmi Vallamkondu; Viswakalyan Kolli; Sarbani Dey Ray; Arubala P Reddy; P Hemachandra Reddy
Journal:  Cells       Date:  2021-11-24       Impact factor: 6.600
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.